Listen to an audio podcast of the June 30, 2022, FDA Drug Safety Communication. Results from a clinical trial show a possible increased risk of death with Copiktra (active ingredient duvelisib) compared to another medicine to treat leukemia and lymphoma.

FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)

FDA Drug Safety Podcasts, produced by FDA's Center for Drug Evaluation and Research, provide emerging safety information about drugs in conjunction with the release of Drug Safety Communications. For more information, please visit: www.fda.gov/drugsafetypodcasts

Share FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)

Sign up to save your podcasts

FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)

FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)